[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Associação Pan-Americana Multidisciplinar de Endocanabinologia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100649443","real-world-evidence-of-cannabinoid-for-observed-pain-relief-100649443",false,"NCT07733791","Real-world Evidence of Cannabinoid for Observed Pain Relief","Topical Use of Cannabinoids (CBD:THC 3:1) as Adjunctive Therapy for Chronic Muscle Pain in Athletes: A Comparative Prospective Observational Study","RECOVER","Inclusion Criteria:\n\n* Predominantly articular, bone, or non-muscular pain (e.g., fractures, degenerative arthropathies)\n* Presence of open skin lesions, infections, or active dermatoses at the topical application site\n* Current use of WADA-prohibited substances that may interfere with outcome assessment\n* Athletes in official competition during the study period using THC-containing formulations (due to WADA in-competition prohibition)\n* Severe acute musculoskeletal injury (complete muscle rupture, fracture) within the last 30 days\n* Cognitive or technological inability to use the follow-up platform\n\nExclusion Criteria:\n\n* Predominantly articular, bone, or non-muscular pain (e.g., fractures, degenerative arthropathies)\n* Presence of open skin lesions, infections, or active dermatoses at the topical application site\n* Current use of WADA-prohibited substances that may interfere with outcome assessment\n* Athletes in official competition during the study period using THC-containing formulations (due to WADA in-competition prohibition)\n* Severe acute musculoskeletal injury (complete muscle rupture, fracture) within the last 30 days\n* Cognitive or technological inability to use the follow-up platform","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","90 Days","OBSERVATIONAL","Chronic muscle pain is one of the most prevalent clinical challenges in sports medicine, significantly affecting training capacity, competitive performance, and quality of life in athletes.\n\nThe endocannabinoid system has emerged as a promising therapeutic target for pain modulation in the sports context.\n\nThis prospective, comparative, non-randomized observational study aims to evaluate whether adjuvant topical application of a cannabinoid balm (CBD:THC 3:1 - Papa \\& Barkley) provides additional reduction in chronic muscle pain intensity in athletes, compared to systemic CBD oil alone, over 90 days of follow-up in a real-world clinical practice setting.\n\nSixty adult athletes (amateur or professional) with established chronic muscle pain (≥3 months) who receive clinical indication for cannabinoid therapy will be followed in two observational cohorts: Cohort A (n=30), receiving only systemic CBD oil (60 mg\u002Fday oral\u002Fsublingual), and Cohort B, (n=30) receiving systemic CBD oil plus the topical cannabinoid balm (CBD:THC 3:1, applied twice daily to the affected muscle area).\n\nTreatment allocation is based exclusively on the clinical decision of the principal investigator, reflecting routine medical practice. The primary outcome is the change in Brief Pain Inventory (BPI) scores from baseline (D0) to end of follow-up (D90). Secondary outcomes include pain intensity (NRS), sleep quality (PSQI), quality of life (SF-36), perceived muscle recovery (TQR scale), functional capacity (LEFS\u002FUEFI), rescue analgesic use, and safety\u002Ftolerability of the topical formulation.\n\nThe study aims to generate real-world evidence on the effectiveness and safety of adjuvant topical cannabinoid therapy in athletes with chronic muscle pain in the Brazilian clinical practice setting.",[26,27],"Chronic Musculoskeletal Pain","Delayed Onset Muscle Soreness (DOMS)",[29,30],"Topical Cannabinoids","Systemic Cannabidiol","NOT_YET_RECRUITING","2026-07-29",{"date":34,"type":35},"2026-07-30","ACTUAL",{"date":37,"type":21},"2027-01-01",{"date":39,"type":21},"2027-07-01",{"name":41,"class":42},"Associação Pan-Americana Multidisciplinar de Endocanabinologia","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100635460","phase-2-cbd-supplementation-in-brazilian-jiu-jitsu-athletes-100635460","NCT07552974","CBD Supplementation in Brazilian Jiu-Jitsu Athletes","Evaluation of the Effects of Isolated Cannabidiol (CBD) on Inflammation, Pain, Sleep and Quality of Life in Brazilian Jiu-Jitsu Athletes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","CBD-BJJ-RCT","Inclusion Criteria:\n\n* Age between 18 and 40 years;\n* Minimum 2 years of BJJ practice;\n* Training at least 3 times per week;\n* Free from injuries that prevent training or competition;\n* No current or recent cannabis use;\n* Signed Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* History of hepatic, renal, or cardiovascular diseases;\n* Use of medications that may interact with CBD (e.g., anticoagulants);\n* Allergy or known hypersensitivity to cannabinoids;\n* Pregnancy or planning to become pregnant;\n* Participation in another clinical study within the last 30 days.",true,"MALE","40 Years",{"count":55,"type":21},100,"INTERVENTIONAL",[58,59],"PHASE2","PHASE3","Brazilian Jiu-Jitsu (BJJ) is a high-intensity martial art that imposes significant physical and physiological demands on practitioners, including rigorous training and frequent competitions, which can result in chronic inflammation, delayed-onset muscle soreness (DOMS), sleep disturbances, and reduced quality of life. Effective recovery strategies are essential to optimize athletic performance and longevity in the sport.\n\nCannabidiol (CBD), a non-psychotomimetic phytocannabinoid derived from Cannabis sativa, has emerged as a promising therapeutic agent due to its anti-inflammatory, analgesic, anxiolytic, and neuroprotective properties.\n\nPreclinical studies indicate that CBD modulates inflammatory pathways, such as inhibition of NF-κB and NLRP3, thereby reducing pro-inflammatory cytokines such as IL-6, TNF-α, IL-8, and IL-1β, while increasing the anti-inflammatory cytokine IL-10.\n\nIn clinical contexts, CBD has shown potential to attenuate DOMS and improve sleep without the adverse effects associated with non-steroidal anti-inflammatory drugs (NSAIDs). However, evidence in BJJ athletes remains limited, with gaps in the translation of preclinical findings to healthy athletic populations.\n\nThe prevalence of injuries in combat sports can reach 28%, with contusions and sprains being common and further exacerbating inflammation and pain. Although approximately 23.4% of athletes report cannabis use, there is a lack of randomized controlled trials (RCTs) specifically for BJJ evaluating isolated CBD at standardized doses.\n\nFurthermore, concerns regarding hepatotoxicity, monitored through enzymes such as AST and ALT, require rigorous safety evaluation.\n\nThis protocol describes an RCT to investigate the effects of 200 mg\u002Fday of isolated CBD for 12 weeks in BJJ athletes, focusing on sensitive inflammatory markers (IL-6 as the primary pro-inflammatory marker and IL-10 as the anti-inflammatory marker), pain, sleep, and quality of life.\n\nThe study aims to address gaps identified in systematic reviews and provide an evidence-based foundation for future recommendations.",[62,63,64,65],"Pro and Anti Inflamatory Cytokines","Pain","Sleep","Quality of Life","2026-07-24",{"date":68,"type":35},"2026-07-27",{"date":37,"type":21},{"date":71,"type":21},"2027-07-31",{"name":41,"class":42},1,""]